Clostridioides difficile infection and recurrence in cancer patients (CIRCA): A multicentre, international study


Por: Puerta-Alcalde, P, O'Keefe, J, Woolstencroft, R, Kaul, S, López, N, Cronin, K, Lim, A, Garcia-Pouton, N, Alvarez, M, Chee, L, Espasa, M, Grafia, I, Suárez-Lledó, M, Smibert, O, Garcia-Vidal, C, Slavin, MA, Yong, MK, Soriano, A and Worth, LJ

Publicada: 1 abr 2025 Ahead of Print: 1 feb 2025
Resumen:
Objectives: We aimed to describe the characteristics of Clostridioides difficile infection (CDI) in cancer patients, analysing risk factors for 90-day recurrence and attributable mortality. Methods: Retrospective analysis on all CDI episodes from 2020 to 2022 in three Australian hospitals and one Spanish hospital. Logistic regression analyses were performed. Results: A total of 547 CDI episodes in cancer patients were documented. Treatment predominantly involved vancomycin (81.5%), followed by metronidazole (15.0%) and fidaxomicin (9.1%). Combined antibiotics were used in 61 (11.2%) episodes. The 90-day recurrence rate was 15.6%. Independent risk factors for CDI recurrence were female sex (OR 2.26, 95% CI 1.13-4.52), age >75 years (OR 2.69, 95% CI 1.30-5.59), dialysis (OR 5.15, 95% CI 1.45-18.27), vomiting at presentation (OR 0.06, 95% CI 0.01-0.55), colonic wall thickening in the CT abdomen (OR 2.42, 95% CI 1.06-5.49) and vancomycin therapy (OR 4.60, 95% CI 1.34-15.84). Overall, 90-day mortality was 22.3%, but attributable mortality was 4.9%. Risk factors for mortality attributed to CDI were age >65 years (OR 15.91, 95% CI 2.64-95.80), previous cerebrovascular disease (OR 20.27, 95% CI 3.12-131.84), antibiotic therapy within the last 30 days (OR 0.17, 95% CI 0.05-0.54), high-output diarrhoea (OR 6.68, 95% CI 1.68-26.56), high CRP-levels (OR 11.60, 95% CI 1.90-70.81) and need for treatment change (OR 6.65, 95% CI 2.20-20.08). Conclusions: CDI recurrence rates among cancer patients remain significant. Nonetheless, fidaxomicin and other preventive strategies are seldom used. We identified several factors that could inform the implementation of these strategies in cancer patients. (c) 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Filiaciones:
:
 Hosp Clin IDIBAPS, Dept Infect Dis, Carrer Villarroel 170, Barcelona 08036, Spain

 Univ Barcelona UB, Barcelona, Spain

O'Keefe, J:
 Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia

Woolstencroft, R:
 Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Natl Ctr Infect, Melbourne, Vic, Australia

Kaul, S:
 Austin Hlth, Dept Infect Dis & Microbiol, Melbourne, Vic, Australia

López, N:
 Hosp Clin IDIBAPS, Dept Infect Dis, Carrer Villarroel 170, Barcelona 08036, Spain

Cronin, K:
 Royal Melbourne Hosp, Microbiol Dept, Melbourne, Vic, Australia

Lim, A:
 Austin Hlth, Haematol Dept, Melbourne, Vic, Australia

Garcia-Pouton, N:
 Hosp Clin IDIBAPS, Dept Infect Dis, Carrer Villarroel 170, Barcelona 08036, Spain

Alvarez, M:
 Hosp Clin IDIBAPS, Ctr Diagnost Biomed, Dept Microbiol, Barcelona, Spain

Chee, L:
 Royal Melbourne Hosp, Haematol Dept, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

Espasa, M:
 Hosp Clin IDIBAPS, Ctr Diagnost Biomed, Dept Microbiol, Barcelona, Spain

Grafia, I:
 Hosp Clin IDIBAPS, Hosp Clin, Barcelona, Spain

Suárez-Lledó, M:
 IDIBAPS, Dept Haematol, Barcelona, Spain

Smibert, O:
 Austin Hlth, Dept Infect Dis & Microbiol, Melbourne, Vic, Australia

Garcia-Vidal, C:
 Hosp Clin IDIBAPS, Dept Infect Dis, Carrer Villarroel 170, Barcelona 08036, Spain

 Univ Barcelona UB, Barcelona, Spain

 CIBERINF CIBER Infect Dis, Barcelona, Spain

Slavin, MA:
 Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Natl Ctr Infect, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Melbourne, Vic, Australia

 Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia

Yong, MK:
 Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Natl Ctr Infect, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Melbourne, Vic, Australia

Soriano, A:
 Hosp Clin IDIBAPS, Dept Infect Dis, Carrer Villarroel 170, Barcelona 08036, Spain

 Univ Barcelona UB, Barcelona, Spain

 CIBERINF CIBER Infect Dis, Barcelona, Spain

Worth, LJ:
 Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Natl Ctr Infect, Melbourne, Vic, Australia

 Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Melbourne, Vic, Australia

 Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
ISSN: 12019712





International Journal of Infectious Diseases
Editorial
Elsevier BV, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Países Bajos
Tipo de documento: Article
Volumen: 153 Número:
Páginas:
WOS Id: 001424592100001
ID de PubMed: 39818267
imagen Green Submitted, gold

MÉTRICAS